warfarininduced skin necrosis condition skin subcutaneous tissue necrosis tissue death occurs due acquired protein c deficiency following treatment antivitamin k anticoagulants warfarin necrosis rare severe complication treatment warfarin related typical patient appears obese middle aged woman median age years male female ratio drug eruption usually occurs third tenth days therapy warfarin first symptoms pain redness affected area progress lesions develop sharp border become petechial hard purpuric may resolve progress form large irregular bloody bullae eventual necrosis slowhealing eschar formation favored sites breasts thighs buttocks areas subcutaneous rare cases fascia muscle development syndrome associated use large loading doses start warfarin necrosis usually occurs three five days drug therapy begun high initial dose increases risk warfarininduced necrosis develop sites local injection infused intravenously widespread warfarins initial stages action inhibition protein c factor vii stronger inhibition vitamin kdependent coagulation factors ii ix x results fact proteins different halflives six hours factor vii eight hours protein c versus one day factor ix two days factor x two five days factor ii larger initial dose vitamin kantagonist pronounced differences coagulation factor imbalance leads paradoxical activation coagulation resulting hypercoagulable state thrombosis blood clots interrupt blood supply skin causing necrosis protein c innate anticoagulant warfarin decreases protein c levels lead massive thrombosis necrosis gangrene limbs notably prothrombin time international normalized ratio inr used test effect warfarin highly dependent factor vii explains patients therapeutic inr indicating good anticoagulant effect still hypercoagulable one third cases warfarin necrosis occurs patients underlying innate previously unknown deficiency protein c condition related purpura fulminans complication infants sepsis also involves skin necrosis infants often protein c deficiency well also cases patients deficiency including protein activated protein c resistance factor v antithrombin iii although hypothesis commonly accepted others believe hypersensitivity reaction direct toxic many conditions mimic may mistaken warfarin necrosis including pyoderma gangrenosum necrotizing fasciitis warfarin necrosis also different another drug eruption associated warfarin purple toe syndrome usually occurs three eight weeks start anticoagulation therapy report described disorder immediate postpartum period patients protein vitamin used reverse effects warfarin heparin low molecular weight heparin lmwh used attempt prevent clotting none suggested therapies studied clinical trials heparin lmwh act different mechanism warfarin drugs also used prevent clotting first days warfarin therapy thus prevent warfarin necrosis called bridging first element treatment usually discontinue offending drug although reports describing eruption evolved little established spite continuing based assumption low levels protein c involved underlying mechanism common treatments setting include fresh frozen plasma pure activated protein since clotpromoting effects starting administration transitory patients protein c deficiency previous warfarin necrosis still restarted drugs appropriate measures include gradual increase starting low doses supplemental administration protein c pure fresh frozen necrotic skin areas treated conditions sometimes healing spontaneously without scarring sometimes going require surgical debridement skin skin necrosis patients previously described verhagen first publish paper relationship medical literature httpsenwikipediaorgwikiwarfarinnecrosis